Kardigan (KARD) Stock Price, News & Analysis

Company Overview

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Key Stats

• Today's Range: $19.99 to $20.93
• 50-Day Range: $19.82 to $25.90
• 52-Week Range: $16.25 to $27.00
• Volume: 196,556 shs
• Average Volume: 235,121 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.25
• Consensus Rating: Moderate Buy

Kardigan Stock Analysis - MarketRank™

Kardigan scored higher than 73% of companies evaluated by MarketBeat, and ranked 212th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kardigan has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Kardigan has a consensus price target of $42.25, representing about 111.0% upside from its current price of $20.02.

Amount of Analyst Coverage

Kardigan has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kardigan are expected to grow in the coming year, from ($5.14) to ($3.35) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.07% of the float of Kardigan has been sold short.

Short Interest Ratio / Days to Cover

Kardigan has a short interest ratio ("days to cover") of 9.28.

Change versus previous month

Short interest in Kardigan has recently increased by 22.58%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kardigan does not currently pay a dividend.

Dividend Growth

Kardigan does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.14

News Sentiment

Kardigan has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.96 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Kardigan this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for KARD on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Kardigan in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $40,000,000.00 in company stock, which represents 2.1369% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Kardigan insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,000,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Kardigan has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 8/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KARD
• CIK: 2123613
• Web: www.kardigan.bio
• Phone: 415-573-3220
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kardigan: $42.25
• High Price Target: $46.00
• Low Price Target: $37.00
• Potential Upside/Downside: +111.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 93,500,000
• Free Float: N/A
• Market Cap: $1.87 billion
• Optionable: N/A
• Beta: N/A